News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

SRI International To Conduct Preclinical Studies Of Cancer Drug For Taiwan Liposome Company


10/3/2006 10:48:22 AM

MENLO PARK, Calif.--(BUSINESS WIRE)--SRI International, an independent nonprofit research and development organization, today announced it has signed an agreement with Taiwan Liposome Company (TLC), a biopharmaceutical company, to begin preclinical safety and toxicology studies of a new cancer drug developed by TLC. The studies will be conducted in support of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA).

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES